Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT

Geron Corporation (NASDAQ:GERN) is one of the 13 Best American Penny Stocks to Invest In. On January 29, TD Cowen analyst Tara Bancroft reduced the firm’s price target on Geron Corporation (NASDAQ:GERN) from $4 to $3 and maintained a Buy rating on the stock. This update comes before the company’s fourth-quarter results, which the company plans to report on February 25.

In other news, on January 12, Geron Corporation (NASDAQ:GERN) shared its financial guidance for 2026. The company expects RYTELO net product revenue to be between $220 million and $240 million. Total operating expenses are projected to range from $230 million to $240 million. Geron Corporation (NASDAQ:GERN) said its 2026 outlook reflects expected revenue growth along with a year-over-year reduction in operating expenses, which it believes supports the strength of its balance sheet.

Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT

For 2026, Geron Corporation (NASDAQ:GERN) said its main priorities include growing RYTELO commercially in the US, exploring opportunities to expand RYTELO into lower-risk myelodysplastic syndromes (LR-MDS) markets outside the US, and advancing its Phase 3 IMpactMF trial.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapies for patients with blood cancers.

READ NEXT: 15 AI Stocks That Are Skyrocketing and 12 Best Oil and Gas Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.